Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

C. Ng, Siew; Hilmi, Ida; Blake, Aimee; Bhayat, Fatima; Adsul, Shashi; Khan, Qasim; Wu, Deng‐Chyang

doi:10.1093/ibd/izy153

Public

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Published in Inflammatory Bowel Diseases • May 4, 2018

Authors:

Siew C. Ng

Ida Hilmi

Aimee Blake

Abstract

Background: Vedolizumab (ENTYVIO) is a humanized α4β7 integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. Method...

Subject

Vedolizumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!